• Explore /
  • Poster
  • / Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

Abstract Video & Slides Poster

Authors

null

Anthony B. El-Khoueiry

University of Southern California, Los Angeles, CA

Anthony B. El-Khoueiry , Richard D. Kim , William Proctor Harris , Max W. Sung , Dirk Waldschmidt , Roniel Cabrera , Vittorio Luigi Garosi , Hong Zebger-Gong , Barbara J. Brennan , Ying A. Wang , Udo Mueller , Tatiane Cristine Ishida , Peter R. Galle

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03347292

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4078)

DOI

10.1200/JCO.2021.39.15_suppl.4078

Abstract #

4078

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Richard D. Kim

First Author: Anthony B. El-Khoueiry

First Author: Jamie Grossman

First Author: Richard S. Finn